The most common symptoms include fatigue, pale or yellow skin, difficulty concentrating, headaches, gastrointestinal upset, depression, and numbness or tingling in the hands or feet
In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
Ready when you are
While injections do have systemic (whole-body) anti-inflammatory benefits, the oral route remains the champion for targeted gut repair
These injections are typically administered subcutaneously (just under the skin) one to three times per week, depending on your providers guidance
Strict Quality Control: 100% inspection of finished products with experienced QA/QC inspectors